Zelboraf Pricing In Germany Still Tied Up By Crossover Trial Design
This article was originally published in The Pink Sheet Daily
Executive Summary
IQWiG reiterates its “considerable added benefit” rating for the melanoma drug, but pricing negotiations will reopen in 2014.